Oz Medicann

Medicinal Cannabis Pharmaceuticalsozmedicann.com

Oz Medicann Group Pty Ltd (trading as OMG Pharma) is an Australian medicinal biotech founded in 2017 that develops evidence-led natural medicines for Sleep, Arthritis, Endometriosis, Fungal Infections, and Anxiety, sold B2B to healthcare providers and research partners.

Company typePrivate
Founded2017
HeadquartersSydney, Australia
Headcount1–10
GTM typeB2B
OfferingHardware or Manufacturing

What Oz Medicann does

Oz Medicann Group Pty Ltd, trading as OMG Pharma, is a privately held Australian medicinal biotechnology company founded in 2017 and headquartered in Sydney. The company develops and commercialises a portfolio of evidence-led natural medicines targeting five therapeutic areas: Sleep, Arthritis, Endometriosis, Fungal Infections, and Anxiety. It self-describes as a 'fully licenced Australian medicinal biotech' and emphasises rigorous scientific research, Australian-made production, and purity/safety as core attributes of its product platform.

The firm operates a B2B go-to-market model positioned as a 'trusted B2B, research and medical partner', engaging healthcare providers (HCPs) through a dedicated HCP Portal on its corporate website rather than through direct-to-consumer retail. Its primary customer segments are patients with therapeutic needs in the five named areas and healthcare providers as a business unit, with use cases spanning treatment, research partnerships, and clinical collaboration. The company has not disclosed pricing, named customers, funding rounds, management team, patents, awards, or M&A activity in the available data. The technology stack is described generically as 'natural medicines developed through rigorous scientific research', with no proprietary AI, software platform, or digital product disclosed beyond the marketing website and HCP portal.

Oz Medicann firmographics

Firmographics

Name: Oz Medicann
Legal name: Oz Medicann Group Pty Ltd
Website: https://ozmedicann.com
Company type: Private
Founded year: 2017
Operating status: Operating
Headcount range: 1–10 employees
Short description: Oz Medicann Group Pty Ltd (trading as OMG Pharma) is an Australian medicinal biotech founded in 2017 that develops evidence-led natural medicines for Sleep, Arthritis, Endometriosis, Fungal Infections, and Anxiety, sold B2B to healthcare providers and research partners.
Ownership category
akta.pro rank

Oz Medicann industry classification

Industry

Product category: Medicinal Cannabis Pharmaceuticals
NAICS: Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC: Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro primary industry: Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
akta.pro secondary industries: Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

Medicinal cannabis
Natural medicines
Pharmaceutical biotech
Cannabis therapeutics
Medicinal biotech

Where Oz Medicann is headquartered

Location

Headquarters

HQ city: Sydney
HQ country: Australia
HQ region: Oceania

Offices1 record

Markets served

Oz Medicann business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

Natural Medicine Products: Revenue generated from the development and commercialization of evidence-led natural medicinal products for therapeutic applications in sleep, arthritis, endometriosis, fungal infections, and anxiety.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Oz Medicann product offering

Product offering

Core offering

Oz Medicann (trading as OMG Pharma) is an Australian medicinal biotechnology company that develops evidence-led natural medicines targeting five therapeutic focus areas: Sleep, Arthritis, Endometriosis, Fungal Infections, and Anxiety. The company operates as a fully licensed Australian medicinal biotech, advancing natural medicines through rigorous scientific research and distributing products via trusted B2B, research, and medical partnerships, including a dedicated HCP (Healthcare Provider) Portal.

Product overview

Oz Medicann (trading as OMG Pharma) is an Australian medicinal biotech company offering a portfolio of evidence-led natural medicines. The company develops therapeutic products across five core focus areas: Sleep, Arthritis, Endometriosis, Fungal Infections, and Anxiety. As a fully licensed Australian medicinal biotech, the company advances natural medicines through rigorous science and trusted B2B, research, and medical partnerships, delivering Australian-made natural medicine products for patients and partners.

Differentiator

Problem solved

Functional benefit

Products and services

Natural Medicines for Sleep
Natural Medicines for Arthritis
Natural Medicines for Endometriosis
Natural Medicines for Fungal Infections
Natural Medicines for Anxiety

Companies that use Oz Medicann

Customer profile

Segments2 records

Ideal customer profiles1 record

Oz Medicann technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Oz Medicann partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Oz Medicann competitors and assessment

Company assessment

Broad incumbents

Jazz Pharmaceuticals: Global biopharmaceutical company that owns GW Pharmaceuticals and the cannabinoid medicines Sativex and Epidiolex. Comparable as a broad incumbent operating in the prescription cannabinoid therapeutics space with proven regulatory and commercial capabilities.
Tilray Brands: Global cannabis leader with a portfolio that includes medicinal cannabis products distributed in Australia and other markets. Comparable as a broad incumbent operating in the same medicinal cannabis category, though much larger and not Australia-only.

Direct peers

Althea Group Holdings: Australian medicinal cannabis company selling a range of cannabinoid products through an HCP-led model with a focus on patient access. Directly comparable GTM and regulatory positioning.
Little Green Pharma: Australian-listed medicinal cannabis company producing cannabinoid-based therapeutic products for sleep, pain, and other indications, distributed through HCPs and pharmacies. Highly comparable as a fellow licensed Australian natural-medicine operator targeting overlapping therapeutic areas.
Incannex Healthcare: ASX-listed clinical-stage cannabinoid pharmaceutical developer focused on treating specific medical conditions with cannabinoid-based therapies. Comparable as an evidence-led medicinal cannabis therapeutics developer targeting defined indications.
Cann Group: Australian-listed medicinal cannabis cultivator and product developer supplying cannabinoid medicines to patients and researchers. Comparable as a licensed Australian cannabis biotech operating across multiple therapeutic applications via B2B channels.

Emerging players

Zelira Therapeutics: Australia-based cannabinoid medicines company developing clinically validated products for pain, sleep, and autism-related indications. Comparable for its evidence-based, indication-focused approach to medicinal cannabis.
Botanix Pharmaceuticals: Clinical-stage cannabinoid therapeutics developer focused on dermatology and other specific indications. Comparable as a science-driven developer of pharmaceutical-grade cannabinoid products targeting defined therapeutic areas.

Regional players

Medlab Clinical: Australian biotech developing pharmaceutical-grade cannabis-based medicines with focus on chronic pain and mental health indications. Comparable for its Australian base and pharmaceutical-grade approach to cannabinoid drug development.

Others

Cronos Group: Global cannabinoid company with branded medicinal and consumer products across multiple geographies. Comparable only at the category level as a broad incumbent in the global medicinal cannabis ecosystem rather than as a direct Australian-market competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Oz Medicann financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oz Medicann leadership team

Management profile

Number of profiles

Oz Medicann funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oz Medicann M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oz Medicann

What does Oz Medicann do?

Is Oz Medicann a public or private company?

Oz Medicann is a private company. It is classified as unknown and is currently operating.

When was Oz Medicann founded?

Oz Medicann was founded in 2017. It employs 1 to 10 people.

Where is Oz Medicann based?

Oz Medicann is headquartered in Sydney, Australia, in the Oceania region.

How does Oz Medicann make money?

One revenue line is on record: natural Medicine Products.

Who are Oz Medicann's main competitors?

Broad incumbents on record are Jazz Pharmaceuticals and Tilray Brands. Direct peers are Althea Group Holdings, Little Green Pharma, Incannex Healthcare and Cann Group. Emerging players are Zelira Therapeutics and Botanix Pharmaceuticals. Medlab Clinical is listed as a regional player. Cronos Group is listed as an others.

Does Oz Medicann have an API?

No public API is recorded for Oz Medicann.

What industry is Oz Medicann in?

Oz Medicann's product category is Medicinal Cannabis Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325411 and its SIC code is 2834.